Allogene Therapeutics (ALLO) vs CorMedix (CRMD)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 18, 2026.
Summary
Allogene Therapeutics (ALLO) has outperformed CorMedix (CRMD) over the past year, gaining 6.5% versus a loss of 28.7%. Over five years, CRMD leads with a +52.8% price change compared with -91.7% for ALLO. CorMedix is the larger company by market cap ($565.9 million vs $452.6 million), about 1.3 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ALLO | CRMD |
|---|---|---|
| Share price | $1.31 | $7.26 |
| Market cap | $452.59M | $565.88M |
| 1-day change | -2.24% | -2.68% |
| YTD return | -4.38% | -37.58% |
| 1-year return | +6.50% | -28.68% |
| 5-year return | -91.72% | +52.84% |
| P/E ratio (TTM) | — | 3.54 |
| Forward P/E | — | 20.74 |
| EPS (TTM) | $-0.66 | $2.05 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $0 | $311.71M |
| Revenue growth (YoY) | -100.00% | +617.03% |
| Net income (latest FY) | $-190.89M | $163.06M |
| Gross margin | — | 88.46% |
| Operating margin | — | 48.17% |
| Net margin | — | 52.31% |
| 52-week high | $4.46 | $13.02 |
| 52-week low | $1.04 | $6.13 |
| Distance from 52-week high | -70.63% | -44.24% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +587.02% | +111.16% |
| Average volume | 5.66M | 1.11M |
| Shares outstanding | 345.49M | 77.94M |
| Employees | 150 | 191 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ALLO has outperformed CRMD by 35.2 percentage points over the past year.
- CorMedix grew revenue faster in its latest fiscal year (+617.03% vs -100.00%).
About Allogene Therapeutics
ALLO stock →Allogene Therapeutics, Inc. a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer and autoimmune diseases.
Healthcare · Biotechnology · 150 employees
About CorMedix
CRMD stock →CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for life-threatening diseases and conditions in the United States. Its lead product candidate is DefenCath, an antimicrobial catheter lock solution to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure.
Healthcare · Biotechnology · 191 employees
ALLO vs CRMD FAQ
Which is bigger, Allogene Therapeutics or CorMedix?
CorMedix (CRMD) is larger, with a market capitalization of $565.88M compared with $452.59M for Allogene Therapeutics (ALLO).
Which stock has performed better over the past year, ALLO or CRMD?
ALLO returned +6.50% over the past 12 months, compared with -28.68% for CRMD (price return, excluding dividends). Past performance does not predict future results.
Are Allogene Therapeutics and CorMedix in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.